Items where authors include "Shawi, M."

Article

Ritchlin, C.T. orcid.org/0000-0002-2602-1219, Deodhar, A. orcid.org/0000-0002-2130-1246, Boehncke, W. et al. (8 more authors) (2023) Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR Open Rheumatology, 5 (3). pp. 149-164. ISSN 2578-5745

Conference or Workshop Item

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, PA.

Proceedings Paper

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2023) P176 Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. , pp. 4182-4184.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4214-4216.

Tillett, W., Coates, L., Sharaf, M. et al. (7 more authors) (2022) 2142: Strong Correlation Between Short- vs Long-form Composite Measures ofPsoriatic Arthritis Disease Activity in a TNFi-IR Population Treated withGuselkumab: Data from the Phase 3b COSMOS Trial. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4248-4251.

Gladman, D.D., Mease, P.J., Bird, P. et al. (13 more authors) (2022) AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1574-1575.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 818-819.

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 832-833.

Tillett, W., Coates, L., Neuhold, M. et al. (6 more authors) (2022) POS1043 Strong Correlation Between Short- Vs Long-Form Composite Measures Of Psoriatic Arthritis Disease Activity In A TNFi-IR Population Treated With Guselkumab: Data From The Phase 3b Cosmos Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 838-839.